Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Enters into Merger Agreement with PointR Data to Leverage Disruptive AI Technology in Its Innovation-Driven Quest for a Cure of Cancer
AGOURA HILLS, Calif. and SANTA CLARA, Calif. , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) and PointR Data Inc. (PointR), a privately-held, developer of high performance cluster computer and artificial intelligence company, announced today that they have
View HTML
Toggle Summary Oncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced Pivotal Phase 3 Clinical Testing
AGOURA HILLS, Calif. , July 30, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, announced today that its team members will participate and provide clinical
View HTML
Toggle Summary Internationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of Oncotelic
AGOURA HILLS, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic"), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to development of innovative treatments for cancer, announced today that Dr. John H. Sampson , an internationally recognized
View HTML
Toggle Summary Oncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory Board
AGOURA HILLS, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB: MATN) dedicated to development of innovative treatments for cancer announced today that four internationally recognized clinical scholars have joined
View HTML
Toggle Summary Mateon and Oncotelic Report on Continuing Integration of the two Businesses
-Relocation of Corporate Headquarters    -Introduction of Amit Shah as incoming CFO    -Presentation of Integrated Pipeline at BIO2019 AGOURA HILLS, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN), a biopharmaceutical company developing investigational drugs for
View HTML
Toggle Summary Mateon Reports First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 15, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, announced today financial results for the first quarter of 2019.
View HTML
Toggle Summary Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline
-Merger creates a publicly-traded clinical stage immuno-oncology company developing treatments for advanced cancers including aggressive brain tumors, pancreatic cancer, and melanoma   -Phase 2 clinical data on lead product candidate OT-101 demonstrated robust tumor responses including complete
View HTML
Toggle Summary Mateon Enters into Merger Agreement with Oncotelic
Forms Late Clinical-Stage Cancer Immunotherapy Company Focusing on TGF-β RNA Therapeutics SOUTH SAN FRANCISCO, Calif. and AGOURA HILLS, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc. , a privately-held, late clinical-stage cancer immunotherapy
View HTML
Toggle Summary Mateon Therapeutics Reports Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced third quarter 2018 financial results.  For the three months ended
View HTML
Toggle Summary Mateon Therapeutics to Present at the Rodman & Renshaw Investor Conference on September 6, 2018
SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications, today announced it will provide an overview of the company and its programs at the 20 th Annual
View HTML